Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells

Fig. 4

Ingenuity Pathway Analysis (IPA) and validation of differentially expressed genes in DFX-treated hmBM-HS/PCs. a Top 10 canonical pathways identified by IPA “Core Analysis” from genes changed more than 1.1-fold (p ≤ 0.05). Bars represent −log (p value) for significance; orange lines represent the ratio of changed genes to the total number of genes in the specific pathway. The IPA predicted one pathway having a positive z-score (predicted activation, orange bar), one pathway with a negative z-score (predicted inhibition, blue bar), 5 pathways having no activity/inhibition pattern predictable, in which the z-score could not be calculated. The z-score of zero corresponded to the standard mean of the normal distribution curve. b Real-time PCR of differentially expressed genes in CD34+ hmBM-HS/PCs treated with DFX. Quantitative reverse transcriptase polymerase chain reaction analysis is shown for transcripts of OAS1, OAS3, IFIT1, ISG15, IRF7, EIF2KA, IFITM3, IFITM2 and IFITM1 in HS/PCs treated with 100 μM DFX for 24 h. The values are the mean ± SD of normalized transcript levels of three independent experiments performed with different preparations of HS/PCs isolated from different donors. Per gene evaluated, fold change value of the transcript level in DFX-treated cells compared to that of untreated cells (CTRL) is reported inside the bar (*p < 0.05 vs CTRL; **p < 0.01 vs CTRL)

Back to article page